0 patents currently held, every record listed here
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
This portfolio holds none of the 6 US patents in force on its record. from the record
Of the 6 now held by other companies, 6 name Eli Lilly and Company as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
none
Next term end
When these terms end
Each bar runs from grant to computed term end. 2010 to 2033.
US 7,718,609
Rapid Acting and Long Acting Insulin Combination Formulations
no later than Aug 21, 2027
US 9,381,247
Magnesium Compositions for Modulating the Pharmacokinetics and Pharmacodynamics of Insulin and Insulin Analogs, and Injection Site Pain
Mar 14, 2033
US 9,399,065
Magnesium Compositions for Modulating the Pharmacokinetics and Injection Site Pain of Insulin
Mar 14, 2033
20152020202520302033
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
Every computed term in this portfolio is shown above.Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
None of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends Mar 2033 · High confidence
The most cited patent in this portfolio, cited by 52 later US patents, top 10% of utility patents granted in 2016 in our data. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
now held by Eli Lilly and Company
Also notable
Ends no later than Aug 2027 · Medium confidence
Cited by 51 later US patents, top 25% of utility patents granted in 2010 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
now held by Eli Lilly and Company
Also notable
Ends Apr 2030 · High confidence
Cited by 24 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2030.
now held by Eli Lilly and Company
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first.
Also on record: 6 patents in force now held by others · 4 patents ended · 5 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
2 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed
2 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.